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INTRODUCTION 
A computer optimization technique, based on response-
surface methodology has proven to be a useful approach for 
selecting pharmaceutical formulations. Factorial designs 
are the most popular response surface designs 1-2. A 
factorial design for two factors at three levels (32) which is 
equivalent to a central composite design (CCD) for two 
factors was selected to optimize varied response variables 
viz. release rate exponent (n), t50%, k, amount of drug 
released in 12h (Rel12h) and mean dissolution time MDT 3-
5. 
 Chlorphenirame maleate is an alkylamine derivative with 
the properties and uses of the antihistamines and generally 
causes less sedation. It antagonizes actions of histamine at 
the H1 receptors. Doses – Usually 4mg, 3-4 times daily, 
higher doses up to 36mg daily, in sustained release 
preparations are given. It is used in conditions like Allergic 
Disorders , Renal failure ,Common Cold and others 6,7.  
Matrix tablet is the least complicated approach in devising 
a sustained release dosage form and involves the direct 
compression of blend of drug, retardant material, and 
additives to form a tablet in which the drug is embedded in 
a matrix core of the retardant.  Hydrophilic matrices are 
well mixed composite of one or more drugs with a 
hydrophilic polymer. Hydrophilic matrices possesses major 
advantages over other alternatives in developing oral 
controlled release drug delivery as they have a capacity to 
incorporate large doses of drugs, these can’t be 
disintegrated throughout the GI tract so the dose dumping 
is not there 8-12. 
In the current study different grades of HPMC like K4M, 
K15M and K100M were selected during preliminary 
studies for regulating the release of the drug 
chlorphenirame maleate.  Two polymers HPMCK4M and 
HPMCK15M were further selected for optimization studies 
13-15. 
Sustained release of drug is required to reduce the 
frequency of administration.  Therefore the object of 
present study is to enable a simpler method of manufacture 
of tablets to provide sustained release of the drug content 
up to 12 hrs. 
 MATERIALS UNDER METHODS 
Chlorphenirame maleate was obtained as a gift sample 
from Promed Labs. Ltd, Indore, (M.P.),  HPMC(K4M, 
K15M, K100M) were  provided by Colorcon India Ltd., 
Goa, dicalcium phosphate, microcrystalline cellulose  
(Avicel PH101), purified  talc , magnesium stearate and all 
other reagent used were of analytical grade. 
Pre-optimization studies 
Nine formulations employed for pre-optimization 
investigations containing different ratios of HPMCK4M, 
HPMCK15M and HPMCK100M, keeping the total tablet 
weight constant at 120mg. The tablets were prepared by 
direct compression. The values of response variables viz. n, 
rel12h, MDT, t50%, t70% and t80% were studied to help in 
choosing the best possible combination for further 
optimization studies.  
Factorial Design 
The 32 factorial designs were selected using two factors 
(polymers) at three levels and the factor levels were 
suitably coded. Nine formulations were prepared as per the 
design and coded F1-F9. The two polymers HPMC K4M 
and HPMC K15M were selected and their limits were 
chosen for subsequent detail studies using the factorial 
design. The amount of drug, magnesium stearate, MCC and 
talc were kept constant while dicalcium phosphate was 
taken in sufficient quantity to maintain a constant tablet 
weight of 120mg. The translation of the coded factor level 
as amount of ingredients is listed in Table (1). 
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Table 1: Translation of experimental conditions into physical units 
Coded Factor Level Factor(X1) Factor (X2) Units 
HPMC K4M HPMC K15M 
-1 
0 
1 
Low 
Intermediate 
High 
25 
35 
45 
15 
22.5 
30 
mg 
mg 
mg 
 
Preparation of Tablets and Physical Evaluation 
Tablet batches consisting of 100 tablets were prepared by 
direct compression method. All the product and process 
variables other than the concentration of two polymers 
were kept constant. The composition of nine formulations 
F1-F9 as per factorial design during optimization studies 
are shown in Table (2a.). Ten tablets from each batch were 
weighed individually and subjected to physical evaluation. 
Dissolution Studies 
Dissolution studies were carried out for all the nine 
formulations in triplicate, employing dissolution USPXXII 
paddle apparatus, using distilled water pH 6.3 as the 
dissolution medium at 50 rpm and 37  0.50C. An aliquot 
of sample was periodically withdrawn at suitable time 
intervals and volume replaced with equivalent amounts of 
plain dissolution medium. The samples were analyzed at 
261 nm. 
Data Analysis 
The raw data obtained from in vitro dissolution was 
analyzed using the software. The software has in built 
provisions for calculating the values of amount of drug 
release, percentage of drug release, log fraction released at 
various time interval, log time, mid-point of time intervals 
and rate of drug release 16-18. 
The software also calculates the kinetic constant (K), the 
diffusional release exponent (n) using logarithmic 
transformation, coefficient of determination (R2), standard 
error of estimation (SEOE), significance test,‘t’ values and 
‘p’ valuesare shown in Table (2b). These values are 
calculated from the interpolation option the graphs. The 
response variables, which were considered for optimization 
included, n, mean dissolution time (MDT), release at   12th 
hr (rel12h), t50% were also calculated. Finally, the 
prognosis of optimum formulation was conducted in two 
stages.  First, a feasible space was located and second, an 
exhaustive grid search was conducted to predict the 
possible solutions. The optimum formulation were selected 
by the critical evaluation of the tabulated grid search values 
. 
Preparation of Predicted optimum Formulation 
The tablet formulations were compressed using the chosen 
optimal composition and evaluated for physical test, tablet 
assay and dissolution performance. The observed and 
predicted responses were critically compared. 
 
Table 2a: Composition of different formulations used as per factorial design during optimization studies 
Formulation Code HPMCK4M HPMCK15M Total Polymer Content Units 
F1 25 15 40 mg 
F2 25 22.5 47.5 mg 
F3 25 30 55 mg 
F4 35 15 50 mg 
F5 35 22.5 57.5 m g 
F6 35 30 65 mg 
F7 45 15 60 mg 
F8 45 22.5 67.5 mg 
F9 45 30 75 mg 
 
RESULTS  
Pre-optimization Studies Results  
The data obtained during the pre-optimization studies 
reveals that as the molecular weight or the viscosity of the 
polymer increases, release rate of the drug from the 
formulation decreases. These studies help in the selection 
of the appropriate range of polymer for the further 
optimization studies. 
Physical Evaluation and Assay of Tablet 
 The tablet weights of all the nine batches vary between 120 
and 121 mg, diameter around 7.22mm, thickness between 
2.11 mm to 2.14 mm and tablet hardness between 5.5 to 5.9 
Kg. The assay was performed taking 20 tablets weighed 
and powdered equivalent to about 4mg of chlorphenirame 
maleate shaken with 20ml of 0.05M sulphuric acid for 
5minutes then added 20ml of ether and filtered the acid 
layer. The ether layer was extracted with two quantities 
each of 10ml of 0.05M sulphuric acid. The combined acid 
extracts were made alkaline to litmus paper with 1M 
sodium hydroxide and extracted with two quantities each of 
50 ml of ether. Each ether extract was washed with the 
water and 0.25M sulphuric acid, diluted and measured the 
absorbance of the resulting solution at about 265nm. The 
assay values varied between 95.83% to 98.75% . The tablet 
friability ranged between 0.5 to 0.8%. The physical 
parameters of the manually compressed tablets were found 
within control. 
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Release Profile Studies 
The dissolution parameters of nine formulations as per 
design containing HPMCK4M and HPMCK15M polymer 
combination with different ratios, obtained are shown in the 
Table (2).  The release pattern between percent drug release 
vs. time and plot between cumulative percent drug release 
vs square root of time (Higuchi Plot) are shown in Fig. (1) 
and Fig. (2), respectively. 
 
Table 2b: Dissolution parameters of (HPMCK4M - HPMCK15M) polymer combinations with different ratios 
during optimization studies using 3
2
 factorial design. 
Formulation 
Code 
n k MDT Rel 12 hr Rel 24 hr t 50% 
t 
60% 
t 70% 
t 
80% 
 
T   p value 
F1 0.547 0.3053 3.0938 102.73 N.C.* 2.5 2.916 3.5 4.666 12.422 < 0.0005 
F2 0.5087 0.2884 3.8851 93.0511 N.C.* 2.8125 3.368 3.894 5 12.434 < 0.0005 
F3 0.5046 0.249 5.2737 89.6962 N.C.* 3.666 5.125 6.545 8.57 18.954 < 0.0005 
F4 0.5094 0.2486 5.1873 91.1045 N.C.* 4 5.333 6.571 9.25 15.725 < 0.000< 0.0005 
F5 0.4809 0.2459 6.0035 87.983 N.C.* 4.375 5.714 7.6 10 16.160 < 0.0005 
F6 0.4537 0.2541 6.3933 84.2741 101.352 4.5 5.166 7.25 11 16.206 < 0.0005 
F7 0.4597 0.257 6.0507 85.999 102.077 4.458 4.875 5.875 9.71 13.50 < 0.0005 
F8 0.4443 0.235 8.009 74.996 84.8205 5.214 5.928 9.333 17.33 15.481 < 0.0005 
F9 0.4182 0.2565 7.632 74.0834 93.9749 5.444 7.25 10.666 15.42 40.524 < 0.0005 
N.C. – Not calculated 
 
Figure 1: Plot between percent drug release and time for formulations as per Factorial design 
 
Figure 2: Plot between cummulative percent drug release and square root of time (Higuchi). 
Response Surface Analysis -Calculation of Coefficient 
The coefficients of the polynomial equations for responses 
n, k, Rel 12hr, MDT and t50% are listed Table (3) along 
with their values of R2. Coefficients (B1-B5) were 
calculated with B0 as the intercept using the polynomial 
equation 
Y=B0 + B1X1 + B2X2 + B3X12 + B4X22 + B5X1X2 + 
B6X1X22 + B7X12 X2 + B8X12X22 
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The coefficient of the above equation was calculated by 
regression using the transformed data taken for  Factor 
X1(HPMCK4M) and Factor X2 (HPMCK15M) as shown 
in Table(1). 
The value of R2 is quite high for Rel12h, t50%, n and MDT 
so for these responses, the polynomial equations form 
excellent fits to all the experimental data and statistically 
valid Table (3).  
Table 3:  Values of the coefficient for the polynomial equations and R2 for various response variables of the formulations 
Coefficient n MDT Rel 12th Hr. t 50 
B0 0.481 5.725 87.102 4.108 
B1 -0.040 1.573 -8.400 1.023 
B2 -0.023 0.828 -5.297 0.442 
B3 0.000 -0.150 0.279 -0.045 
B4 -0.001 -0.204 -1.028 -0.276 
B5 0.004 -0.361 2.638 -0.039 
B6 -0.011 -0.733 0.942 -0.267 
B7 0.007 0.337 -2.822 0.288 
B8 0.005 -0.221 4.397 0.129 
R2 0.999845 1.000000 1.000000 1.000000 
 
Search for Optimum Formulations 
The criterion for selection of suitable feasible region was 
primarily based on highest possible values of n, Rel 12 hr, 
MDT and t50%. Two regions were selected on the basis of 
dissolution parameters obtained during optimization studies 
of formulations F1-F9. The exel sheet was used to predict 
and determine the responses between the Region 1 and 
further Region 2, termed as feasible regions for factorX1 
and FactorX2 (HPMCK4M and HPMCK15M).  
Region 1 
rel 12 hr >90%; n > 0.460; MDT > 3.1; t50% > 2.5 hr. 
Region 2 
rel 12 hr >96; n > 0.49; MDT > 3.8; t50% > 3 hr 
 
The predicted values for the responses were noted and are 
shown in Table (4a). Based on the predicted values the 
levels were decoded and factor values were determined 
(refer Table (1). Values obtained for HPMCK4M were 27.2 
mg and HPMCK15M were 18.15 mg. using these amounts 
tablets of optimum formulation was prepared and subjected 
to dissolution studies. The dissolution parameters obtained 
for optimum formulation are shown in Table (4b).  
Table 4a: Predicted values of optimum formulations 
n k MDT Rel12hr t50 t60 t70 t80 
0.5218 3.720 3.8994 96.273 2.81 3.3884 3.894 4.890 
Table 4b: Dissolution parameters of optimum formulation 
n k MDT Rel12hr t50 t60 t70 t80 
0.5215 3.7205 3.7144 95.54 2.80 3.3684 3.8947 4.8889 
 
Comparison of Optimum Formulation 
The results of the physical evaluation and tablet assay of 
the optimum formulation were within limits. Dissolution 
parameters like n, MDT, Rel 12n and k were tabulated 
for optimized matrix tablets formulation and shown in 
Table (4b.). The plot between percent drug release and 
time of the optimized formulation is shown in Fig. (3). 
The comparison of the observed responses with 
anticipated responses along with percent error are listed 
in Table (5). The results obtained of the experimental 
values are very much close to the predicted values for 
the two responses n and Rel12hr.  
Figure 3: Plot between percent drug release and time of 
the optimum formulations 
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Table 5: Comparison of experimental results with predicted responses 
    Composition HPMCK4M/ 
15M 
Response Predicted Value Experimental Value Percentage Error 
27.2/18.15 
n 0.5218 0.5215 0.05 
Rel 12 96.2730 95.54 0.76 
 
DISCUSSION  
The dissolution data indicates that as the content of 
HPMCK4M and HPMCK15M increased, the value of n 
was found to decrease, except when HPMCK4M content 
increased from intermediate to high level. By and large the 
table delineates a decreasing trend in the value of n as the 
ratio of total polymer content to drug increased.  In general 
the release pattern tends to approach Fickian release with 
increase in polymer content. 
The values of k showed however no distinct trend with 
increase in concentration of polymers. The values of 
Rel12h showed that with an increasing total polymer 
content resulted in the decrease in the drug release. The 
inverse relationship is there between the total polymer 
content and drug release. 
The value of overall rate of release decreases with 
increasing concentration of HPMCK4M and HPMCK15M 
from low to intermediate levels. Increasing the 
concentration to high level of HPMCK4M and 
HPMCK15M did not have any significant effect or release 
rate, in accordance with the previous reports, wherein a 
saturation effect occurred at high concentration. The 
general pattern was a decrease in release rate with an 
increase in amount of total polymer content. This is in clear 
accordance with earlier findings. 
The values of MDT showed that with increasing total 
polymer content resulted in the increase of mean 
dissolution time. MDT is used to characterize drug release 
rate from a dosage form and indicates the drug release 
retarding efficiency of polymer.  
Comparisons of the observed responses with that of the 
anticipated responses along with percentage error for 
dissolution parameters like n and Rel 12h of optimized 
matrix tablets formulation shows the prognostic ability of 
matrix tablet formulations of  Chlorpheniramine maleate 
using optimization method and is validated.   
CONCLUSION  
Chlorpheniramine maleate matrix tablets containing 
combination of polymers HPMCK4M and HPMCK15M, 
confirms excellent promises for drug release prolongation. 
Results of the dissolution studies for optimized formulation 
fulfilled maximum requisites because of better regulation 
of release rate. Rational use of optimization methodology 
helped to predict the best possible formulations and 
confirms the prognostic ability of optimization method. 
Using the traditional methods, however, the best 
formulation might have skipped the observations of the 
formulation scientist. Conclusively, the current study 
attained the successful design, development, optimization 
and formulation of chlorpheniramine maleate Tablets. 
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